Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

被引:142
作者
Ishibashi, Yuji [1 ]
Matsui, Takanori [1 ]
Takeuchi, Masayoshi [2 ]
Yamagishi, Sho-ichi [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan
[2] Hokuriku Univ, Fac Pharmaceut Sci, Dept Pathophysiol Sci, Kanazawa, Ishikawa 92011, Japan
关键词
AGE; Atherosclerosis; cAMP; GLP-1; RAGE; ACTIVATOR INHIBITOR-1;
D O I
10.1016/j.bbrc.2009.12.075
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glucagon-like peptide-1 (GLP-1) is one of the incretins, a gut hormone secreted from L cells in the intestine in response to food intake. It has been Proposed as a potential therapeutic target for the treatment of patients with type 2 diabetes. However, the direct effects of GLP-1 on vascular injury in diabetes are largely unknown. Since there is a growing body of evidence that advanced glycation end products (AGE) and their receptor RAGE axis plays an important role in vascular complications in diabetes, this study investigated whether and how GLP-1 blocked the deleterious effects of AGE on human umbilical vein endothelial cells (HUVEC). GLP-1 receptor (GLP-1 R) was expressed in HUVEC. GLP-1 dose-dependently inhibited RAGE gene expression in HUVEC, which was blocked by small interfering RNAs raised against GLP-1R. An analogue of cyclic AMP also decreased RAGE mRNA level in HUVEC. Further, GLP-1 decreased reactive oxygen species generation and Subsequently reduced vascular cell adhesion molecule-1 mRNA levels in AGE-exposed HUVEC. Our present study suggests that GLP-1 directly acts on HUVEC via GLP-1R and it could work as an anti-inflammatory agent against AGE by reducing RAGE expression via activation of cyclic AMP pathways. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:1405 / 1408
页数:4
相关论文
共 15 条
  • [1] Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Herman, Gary A.
    Bergman, Arthur
    Stevens, Catherine
    Kotey, Paul
    Yi, Bingming
    Zhao, Peng
    Dietrich, Bruno
    Golor, George
    Schrodter, Andreas
    Keymeulen, Bart
    Lasseter, Kenneth C.
    Kipnes, Mark S.
    Snyder, Karen
    Hilliard, Deborah
    Tanen, Michael
    Cilissen, Caroline
    De Smet, Marina
    de Lepeleire, Inge
    Van Dyck, Kristien
    Wang, Amy Q.
    Zeng, Wei
    Davies, Michael J.
    Tanaka, Wesley
    Holst, Jens J.
    Deacon, Carolyn F.
    Gottesdiener, Keith M.
    Wagner, John A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) : 4612 - 4619
  • [2] The glucagon-like peptides
    Kieffer, TJ
    Habener, JL
    [J]. ENDOCRINE REVIEWS, 1999, 20 (06) : 876 - 913
  • [3] The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
    Kim, Wook
    Egan, Josephine M.
    [J]. PHARMACOLOGICAL REVIEWS, 2008, 60 (04) : 470 - 512
  • [4] Glucagon-like peptide-1 attenuates tumour necrosis factor-α-mediated induction of plasmogen activator inhibitor-1 expression
    Liu, Hongbin
    Hu, Yunshan
    Simpson, Richard W.
    Dear, Anthony E.
    [J]. JOURNAL OF ENDOCRINOLOGY, 2008, 196 (01) : 57 - 65
  • [5] Pratley Richard E, 2008, Rev Diabet Stud, V5, P73, DOI 10.1900/RDS.2008.5.73
  • [6] Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
    Preiss, D. J.
    Sattar, N.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (04) : 697 - 701
  • [7] Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes
    Takenaka, Katsuhiko
    Yamagishi, Sho-ichi
    Matsui, Takanori
    Nakamura, Kazuo
    Imaizumi, Tsutomu
    [J]. CURRENT NEUROVASCULAR RESEARCH, 2006, 3 (01) : 73 - 77
  • [8] Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients
    Takeuchi, M
    Makita, Z
    Yanagisawa, K
    Kameda, Y
    Koike, T
    [J]. MOLECULAR MEDICINE, 1999, 5 (06) : 393 - 405
  • [9] Immunological detection of a novel advanced glycation end-product
    Takeuchi, M
    Yanase, Y
    Matsuura, N
    Yamagishi, S
    Kameda, Y
    Bucala, R
    Makita, Z
    [J]. MOLECULAR MEDICINE, 2001, 7 (11) : 783 - 791
  • [10] G-protein-coupled receptors and islet function - Implications for treatment of type 2 diabetes
    Winzell, Maria Sorhede
    Ahren, Bo
    [J]. PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) : 437 - 448